Current Cholangiocarcinoma Trials
Listed here are the clinical trials for those with cholangiocarcinoma (bile duct cancer) or gall bladder cancer, currently open and recruiting in the UK.
Wherever possible links for further information have been included to follow up for more information and to check eligibility. Each trial has specific eligibility criteria, so if you are interested in taking part in one, please discuss with those running the trial (contact details are given where possible) and/or your consultant.
Please note it is not appropriate for AMMF to give medical advice or recommendations, and all details provided are for information purposes only.
Clinical trials and COVID-19
In March 2020, at the start of the pandemic, many non-COVID-19 clinical trials were temporarily halted. As of 13 July, while the priority continues to be COVID-19 research, the NIHR (National Institute for Health Research) has stated, wherever possible, the restoration of the broad range of clinical trials should begin. For more information, click here.
Following the outcome of the BILCAP study, those who have undergone a resection for their cholangiocarcinoma or gall bladder cancer, and who fit the eligibility criteria, are now offered Capecitabine chemotherapy as the standard of care.
The ACTICCA-1 trial is a randomized Phase III trial which looks to compare Gemcitabine and Cisplatin against Capecitabine alone (currently the standard treatment) for those who have had a resection for their cholangiocarcinoma or gall bladder cancer:
“Adjuvant Chemotherapy with Gemcitabine and Cisplatin compared to Capecitabine (standard treatment) after Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma”Read More
ABC-07 is a randomised trial for those with locally advanced cholangiocarcinoma. All patients begin by receiving Gemcitabine/Cisplatin chemotherapy and, after 6 cycles of chemotherapy, are then randomized to continuing with the chemotherapy or receiving SBRT (stereotactic body radiotherapy)*
* SBRT (stereotactic body radiotherapy) is a way of targeting radiotherapy beams very precisely at a tumour from many different directions. LINAC or Cyberknife machines may be used to deliver SBRT, depending on the equipment available in a particular hospital.Read More
A first line Phase II trial for inoperable, recurrent and metastatic cholangiocarcinoma (intra- and extrahepatic) and gall bladder cancer patients.
This will be a single arm study of first line Pembrolizumab and Gemcitabine/Cisplatin.
All patients on this trial will receive the immunotherapy drug Pembrolizumab in addition to the Gemcitabine/Cisplatin chemotherapy.Read More
STARTRK-2 is an open-label, global, Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with locally advanced or metastatic solid tumours, and is currently recruiting in 3 centres in the UK.
Cholangiocarcinoma patients would be screened for an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene rearrangement.Read More
NuTide:121 will compare NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients with Advanced Biliary Tract Cancer.
The study opened to recruitment in December 2019 and will enrol up to 828 patients globally. There will be a number of UK sites be participating.
(The NUC-1031 Plus Cisplatin combination was developed through the UK ABC-08 study)Read More
TOPAZ-1: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer.
This is a global study looking at the role of immunotherapy in addition to standard-of-care chemotherapy. All patients will receive chemotherapy (CisGem) and either durvalumab or placebo;
It will be a double-blind study – neither the patient or the treating clinician will know if the patient is receiving durvalumab or not.
This study is open and recruiting at the following UK locations:
Bristol, Cambridge, Royal Free, Hammersmith, The Christie, Queen’s Hospital (Romford) and Sheffield.
FIGHT-302: Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements.
This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR-alteration.Read More
FIGHT-207 is a study to evaluate the efficacy and safety of pemigatinib in those with activating FGFR mutations or translocations.
Full title: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
This multi-centre international study is currently open at two centres in the UK.Read More
A Phase II, Single Arm Study of BGJ398 (infigratinib) in patients with advanced cholangiocarcinoma.
Full title: “A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy”Read More
Current trials no longer recruiting
For information on trials that are no longer recruiting, but are still live, please click here
Trials in set up
For information on trials that are currently in set up, please click here
The NIHR (National Institute for Health Research) “Be Part of Research” website has details of all UK clinical trials. Visit: bepartofresearch.nihr.ac.uk and search for the name or number of the trial you are interested in.
Cancer Research UK also lists clinical trials for bile duct cancer (cholangiocarcinoma). To see this, click here
For information on current treatments for cholangiocarcinoma, click here